Jeschke, M.; Ludwig, J.M.; Leyh, C.; Pabst, K.M.; Weber, M.; Theysohn, J.M.; Lange, C.M.; Herrmann, K.; Schmidt, H.H.-J.; Jochheim, L.S.
Bilobar Radioembolization Carries the Risk of Radioembolization-Induced Liver Disease in the Treatment of Advanced Hepatocellular Carcinoma: Safety and Efficacy Comparison to Systemic Therapy with Atezolizumab/Bevacizumab. Cancers 2023, 15, 4274.
https://doi.org/10.3390/cancers15174274
AMA Style
Jeschke M, Ludwig JM, Leyh C, Pabst KM, Weber M, Theysohn JM, Lange CM, Herrmann K, Schmidt HH-J, Jochheim LS.
Bilobar Radioembolization Carries the Risk of Radioembolization-Induced Liver Disease in the Treatment of Advanced Hepatocellular Carcinoma: Safety and Efficacy Comparison to Systemic Therapy with Atezolizumab/Bevacizumab. Cancers. 2023; 15(17):4274.
https://doi.org/10.3390/cancers15174274
Chicago/Turabian Style
Jeschke, Matthias, Johannes M. Ludwig, Catherine Leyh, Kim M. Pabst, Manuel Weber, Jens M. Theysohn, Christian M. Lange, Ken Herrmann, Hartmut H. -J. Schmidt, and Leonie S. Jochheim.
2023. "Bilobar Radioembolization Carries the Risk of Radioembolization-Induced Liver Disease in the Treatment of Advanced Hepatocellular Carcinoma: Safety and Efficacy Comparison to Systemic Therapy with Atezolizumab/Bevacizumab" Cancers 15, no. 17: 4274.
https://doi.org/10.3390/cancers15174274
APA Style
Jeschke, M., Ludwig, J. M., Leyh, C., Pabst, K. M., Weber, M., Theysohn, J. M., Lange, C. M., Herrmann, K., Schmidt, H. H. -J., & Jochheim, L. S.
(2023). Bilobar Radioembolization Carries the Risk of Radioembolization-Induced Liver Disease in the Treatment of Advanced Hepatocellular Carcinoma: Safety and Efficacy Comparison to Systemic Therapy with Atezolizumab/Bevacizumab. Cancers, 15(17), 4274.
https://doi.org/10.3390/cancers15174274